B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram
| Autor: | Shinzo Miyamoto, Hirofumi Soejima, Yasuaki Tanaka, Jun Hokamaki, Hiroshige Yamabe, Yuji Miyazaki, Yasuhiro Nagayoshi, Hisao Ogawa, Hiroaki Kawano |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cardiac function curve
Chest Pain medicine.medical_specialty medicine.drug_class medicine.medical_treatment Administration Oral Medroxyprogesterone Acetate Administration Cutaneous Coronary Angiography Chest pain Internal medicine Natriuretic Peptide Brain medicine Natriuretic peptide Humans Ventricular Function Cardiac catheterization Estradiol business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Estrogens Middle Aged medicine.disease Postmenopause Menopause Endocrinology Echocardiography Estrogen Female Hormone therapy medicine.symptom business Hormone |
| Zdroj: | Menopause. 15:352-356 |
| ISSN: | 1072-3714 |
| DOI: | 10.1097/gme.0b013e31806548f6 |
| Popis: | OBJECTIVES Coronary heart disease is relatively uncommon in premenopausal women but shows a sharp increase after menopause. The decline of endogenous ovarian hormones is commonly assumed to be a major component of this phenomenon. The effects of estrogens on the vasculature have been investigated extensively in previous studies. However, the effects of estrogens on myocardial function have not been evaluated in humans. We sought to examine the effects of hormone therapy (HT) on myocardial function and cardiac natriuretic peptides in postmenopausal women with chest pain and a normal coronary angiogram. DESIGN Transdermal HT (estradiol: 0.72 mg/2 d) was administered to 15 postmenopausal women with chest pain and a normal coronary angiogram (mean age, 53 y) for 12 weeks, and oral HT (conjugated equine estrogens: 0.625 mg/d) was administered to another 15 postmenopausal women (mean age, 54 y) for 12 weeks. Echocardiography or cardiac catheterization showed no cardiac dysfunction in any woman at baseline. Cardiac function was evaluated by echocardiography, and plasma B-type natriuretic peptide was measured every 4 weeks. RESULTS B-type natriuretic peptide levels increased after transdermal HT (baseline: 13.1 +/- 3.1, 4 wk: 22.1 +/- 2.9, 8 wk: 33.2 +/- 3.1, 12 wk: 38.4 +/- 3.3 pg/mL; P < 0.01 vs baseline). The levels were also augmented after oral HT (baseline: 14.1 +/- 3.8, 4 wk: 23.2 +/- 3.3, 8 wk: 35.6 +/- 3.9, 12 wk: 39.6 +/- 3.5 pg/mL; P < 0.01 vs baseline). Serial echocardiography showed no changes in ventricular function in either treatment group. At baseline the serum estradiol levels in the transdermal group were comparable with those in the oral group. CONCLUSIONS The estradiol levels after HT increased in both groups, but there was no significant difference between the two groups. B-type natriuretic peptide levels increased without cardiac dysfunction, and the chest symptoms were relieved in some participants after HT. Thus, estrogen supplementation augments natriuretic peptide levels without harmful effects on ventricular function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|